


CLAIM AMENDMENTS

1. (currently amended): A compound of the general formula I




I

or pharmaceutically acceptable prodrugs, salts, hydrates, solvates, crystal forms or diastereomers thereof, wherein:

one carbon of ring B is substituted with Z and the rest of the carbons are independently substituted with Y;

A is a ring selected from:



where D is selected from H, C₁₋₄ alkyl, halogen, amino;

W is:










(i) NR¹R² where R¹ and R² are independently H, C₁₋₄ alkyl, C₁₋₄ alkylCF₃, aryl, hetaryl, C₁₋₄ alkylaryl, C₁₋₄ alkylhetaryl, C₃₋₈ cycloalkyl, C₂₋₆ alkenyl, cyclohetalkyl, C₁₋₄ alkylcycloalkyl, C₁₋₄ alkyl cyclohetalkyl, or R¹ and R² are joined to form an optionally substituted 3-8 membered ring optionally containing an atom selected from O, S, NR³; and R³ is selected from H, C₁₋₄ alkyl, aryl, hetaryl, C₁₋₄ alkyl aryl, C₁₋₄ alkyl hetaryl, COR⁴ where R⁴ is selected from H, C₁₋₄ alkyl, aryl, hetaryl; or

(ii) H, C₁₋₄ alkyl, aryl, hetaryl, C₃₋₈ cycloalkyl, cyclohetalkyl, C₁₋₄ alkylaryl, C₁₋₄ alkylhetaryl, C₃₋₈ cycloalkyl, C₁₋₄ alkylcycloalkyl, C₁₋₄ alkyl cyclohetalkyl;

Y is H, halogen, CN, CF₃, nitro, OH, C₁₋₄ alkyl, C₁₋₄ alkylNR⁵R⁶, C₁₋₄ alkylhetaryl, OC₁₋₄ alkyl, OC₂₋₄ alkylOC₁₋₄alkyl, OC₁₋₄ alkylNR⁵R⁶, OC₁₋₄ alkylhetaryl, OC₁₋₄ alkylcyclohetalkyl, SC₁₋₄ alkyl, SC₂₋₄ alkylOC₁₋₄alkyl, SC₁₋₄ alkylNR⁵R⁶, NR⁵R⁶, NR⁵COR⁶, NR⁵SO₂R⁶; and R⁵ and R⁶ are each independently H, C₁₋₄ alkyl, or may be joined to form an optionally substituted

3-6 membered ring optionally containing an atom selected from O, S, NR⁷ and R⁷ is selected from H, C₁₋₄ alkyl, aryl, hetaryl, C₁₋₄ alkylaryl, C₁₋₄ alkylhetaryl;

Z is selected from:



where R⁸ is selected from H, C₁₋₄ alkyl;


R⁹ and R¹⁰ are independently selected from H, C₁₋₄ alkyl, C₁₋₄ alkylNR¹²R¹³, C₁₋₄ alkylOR¹², C₁₋₄ alkylhetaryl or may be joined to form a 5-8 membered ring containing an atom selected from SO, or SO₂;

R¹¹ is selected from OH, OC₁₋₄ alkyl, NR¹²R¹³;

n is 0-4;


where R¹² and R¹³ are independently selected from H, C₁₋₄ alkyl, or may be joined to form an optionally substituted 3-8 membered ring optionally containing an atom selected from O, S, NR¹⁴; and R¹⁴ is selected from H, C₁₋₄ alkyl.


2. (previously presented): A compound according to claim 1 wherein Z is selected from:





wherein R⁸, R⁹, R¹⁰ and R¹¹ and n are as defined in claim 1.

3. (currently amended): A compound selected from the group consisting of:









including the pharmaceutically acceptable salts or diastereomers thereof.

4. (previously presented): A compound according to claim 1, wherein the compound irreversibly inhibits JAK-3.

5. (previously presented): A compound according to claim 1, wherein the compound selectively inhibits JAK 3 with respect to JAK 1 or JAK 2.

6. (previously presented): A composition comprising a carrier and a compound according to claim 1.

7. (withdrawn): A method of treating a tyrosine kinase-associated disease state, the method comprising administering a therapeutically effective amount of a compound according to claim 1 or a pharmaceutical composition thereof.

8. (canceled)

9. (withdrawn): A method of suppressing the immune system of a subject, the method comprising administering a therapeutically effective amount of a compound according to claim 1 or a pharmaceutical composition thereof.

10-13. (canceled)